**TABLE S1 Remarks on the consideration and evaluation of CONSORT criteria [1] across studies**

| CONSORT statement | Consideration in context |
|---|---|
| 1: Title and abstract<br>2a: Scientific background and explanation of rationale | Considered as mainly relevant for publication purposes/transparency and not discussed in depth for each trial in this review |
| 3a: Description of trial design (such as parallel, factorial) including allocation ratio | All trials were open-label, Phase III, randomized trials; this review focuses on the allocation ratio which is part of this criterion |
| 4a: Eligibility criteria for participants | Only those of special interest are included |
| 6b: Any changes to trial outcomes after the trial commenced, with reasons | Any changes to trial outcomes after trial commenced with this criterion the deviation from the initial outcome definition are meant – we are not aware of any and they are not always reported anyway. To be included if any known changes (e.g. change of primary endpoint) occurred. |
| 8a: Method used to generate the random allocation sequence<br>8b: Type of randomisation; details of any restriction (such as blocking and block size)<br>9: Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned<br>10: Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | Applicable information on randomization was summed up under point 8 |
| 11a and b: Blinding | Omitted because all were open-label |
| 14b: Why the trial was ended or stopped | Relevant information on premature stop of the trial is covered under 7b (interim analyses) in the tables included in this review for the sake of conciseness |
| 15: A table showing baseline demographic and clinical characteristics for each group | Not included in the overview tables in this review for the sake of space |
| 17: Outcomes and estimation<br>18: Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | In this review, the outcomes and ancillary analyses are described in the quantitative analysis |
| 19: All important harms or unintended effects in each group | Every trial showed a superior safety profile of the experimental arm over chemotherapy. EGFR-TKI class specific side effects are detailed in the quantitative analysis |

1. Moher D., Hopewell S., Schulz KF., *et al.*: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.:: J Clin Epidemiol 2010; 63: e1–37.